A Chinese or Indian manufacturer can register and sell medicines in Malaysia, but its domestic approval opens no reliance route: NMPA and CDSCO are not among NPRA's recognised reference agencies, so the default is full evaluation. Three things change that picture: WHO prequalification of the product opens a reliance route; an approval of the same product by a recognised agency (EMA, US FDA and five others) does the same; and a manufacturing site holding EU GMP or US FDA status typically faces fewer GMP questions, because NPRA can take existing PIC/S-authority inspection outcomes into account. As for every foreign manufacturer, the registration must be held by a locally incorporated Marketing Authorisation Holder (MAH), appointed through a letter of authorisation.
A note on terms: NPRA officially calls the holder the Product Registration Holder (PRH). Throughout RHMI's guides we use the equivalent international term, Marketing Authorisation Holder (MAH) - they mean the same party.
Our Asia market-entry page gives the regional overview. This article answers the specific questions Chinese and Indian manufacturers actually ask us: what shortens the path, what the dossier needs, and what GMP evidence NPRA will want.
The honest starting position
NPRA's recognised reference agencies are EMA, US FDA, Swissmedic, UK MHRA, Health Canada, PMDA and TGA - plus reliance on ASEAN Joint Assessment outcomes and WHO prequalification. China's NMPA and India's CDSCO are not on the list. In practice: a product approved only at home enters Malaysia through full evaluation, the longest route, on a dossier restructured into the ASEAN Common Technical Document (ACTD). How the routes compare.
That is the default. It is not the ceiling.
Three ways the path gets shorter
1. WHO prequalification
If your product is WHO-prequalified, NPRA accepts that outcome and a reliance route opens. For manufacturers of essential medicines and generics this is often the most realistic shortcut - worth checking your portfolio before planning anything else.
2. A recognised agency's approval of the same product
If the product is also approved by, say, the EMA or US FDA, that approval - not the domestic one - is what you rely on. Abbreviated review targets 90 working days (filed within three years of the reference approval). An FDA approval - or an EMA approval via the centralised procedure (decentralised for generics only) - can also qualify for the 60-working-day recognition pilot, a one-year pilot running since 2 May 2026, if filed within about three months of the reference approval and the product is identical to the approved one (same formulation, strength, indications, sites; no post-approval changes). Larger Indian groups with EU or US registrations often have this card without realising it applies to Malaysia. The fast-track rules in full.
3. EU GMP or US FDA site status
Separate from product reliance: Malaysia is a PIC/S member, and how your manufacturing site's GMP standing is evidenced shapes the quality part of the assessment. A site holding EU GMP or US FDA status typically faces fewer GMP questions, because NPRA can take existing PIC/S-authority inspection outcomes into account. Whatever your certificates, confirm early what GMP evidence NPRA will accept for your specific site - the documentary expectations differ, and this is where entry plans most often lose months.
What the dossier needs regardless of route
- ACTD structure. Filings from China and India typically arrive in ICH CTD; Malaysia registers on the ACTD, so on the standard routes the dossier is restructured (the recognition pilot instead relies on the approved FDA/EMA dossier). CTD to ACTD mapping.
- Certificate of Pharmaceutical Product (CPP), where applicable, from the home authority - which assumes the product is registered at home. Export-only products without a domestic registration hit this wall early and need to resolve it before filing.
- Zone IVb stability data. Malaysia sits in ASEAN Climate Zone IVb (30°C/75% RH - hot and very humid). Many Indian exporters already generate Zone IVb data for ASEAN and African markets - but India's domestic conditions are Zone IVa, so check what your existing studies actually cover. Chinese packages built for temperate markets usually need supplementary studies, and new stability data is measured in months.
- Bioequivalence data for generics, where the product type requires it, from studies NPRA will accept.
- A letter of authorisation appointing the Malaysian holder - the document that formally connects your company to the local MAH.
The structural requirement no certificate removes
Whatever your GMP status, the registration itself must be held by a locally incorporated company. Exporters commonly discover this after finding a buyer and default to letting that buyer hold the registration - which converts a customer into a gatekeeper. The alternative: an independent MAH holds the registration under a contract that fixes your ownership of the dossier and your right to move it, while distribution is negotiated on commercial merit. Who should hold the registration: the decision checklist.
Where RHMI stands - stated plainly
Our registration and MAH services are open to Chinese and Indian manufacturers. What we provide: route assessment, dossier plan and an independent holder for the registration, with import coordinated through a licensed importer partner. Taking a product into our own distribution is a separate, selective decision - and for Chinese and Indian manufacturers our first criterion there is that the manufacturing site holds EU GMP or US FDA status. That is our own commercial standard, not an NPRA rule: it is the profile we can credibly represent to Malaysian buyers and institutions. Holding your registration is never conditional on giving us distribution. What the registration service covers.
Frequently asked questions
Does a Chinese NMPA or Indian CDSCO approval speed up Malaysian registration?
No. Neither is among NPRA's recognised reference agencies, so a domestic approval alone means full evaluation. WHO prequalification or an approval by a recognised agency (EMA, US FDA and others) does open a reliance route.
Is WHO-GMP certification enough for the Malaysian GMP file?
It is a starting point. Malaysia is a PIC/S member and NPRA assesses site documentation on its own terms; confirm early what GMP evidence it will accept for your site - a site with EU GMP or US FDA status typically faces fewer questions, because PIC/S-authority inspection outcomes can be taken into account.
Can we export to Malaysia if the product is not registered in China or India?
The product does not need a Malaysian history, but a Certificate of Pharmaceutical Product from your home authority is a standard expectation - and it assumes home registration. Export-only products should resolve this before planning a filing.
Do we need our own company in Malaysia?
No - and you cannot hold the registration from abroad either way. You appoint a locally incorporated MAH through a letter of authorisation: a distributor, your own subsidiary, or an independent holder.
Will our stability data be accepted?
Malaysia requires data for ASEAN Climate Zone IVb (30°C/75% RH). Many Indian exporters already hold Zone IVb data generated for ASEAN and African markets, but India's domestic conditions are Zone IVa - check what your studies actually cover. Data built for temperate markets usually needs supplementation; budget months, not weeks, if new studies are needed.
You might also find useful
- Malaysia Market Entry for Asian Pharma Manufacturers
- Drug Registration in Malaysia: Process, Timeline and Requirements
- Independent MAH vs Distributor as MAH in Malaysia: The Decision Checklist
- Sources:
- NPRA Drug Registration Guidance Document (DRGD): npra.gov.my (DRGD)
- NPRA - Facilitated Registration Pathway and recognition pilot (from 2 May 2026): npra.gov.my
- RAPS - Malaysia's NPRA updates regulatory reliance guide: raps.org
- PIC/S - List of Participating Authorities: picscheme.org
- Editorial note: This page is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal or regulatory advice. Eligibility, documentary requirements and timelines are administrative details that change; confirm them against NPRA's current guidance before acting. Last reviewed against NPRA guidance: 4 September 2026.